Magnetic Resonance Imaging trials for Lung cancer

All Magnetic Resonance Imaging trials · All Lung cancer trials

Phase breakdown

Recruiting trials studying Magnetic Resonance Imaging for Lung cancer

• 4D-MRI for Precision Medicine
  NCT04657042 · Phase: Not specified · Ages: 18 Years to 82 Years · Sex: All (male and female) · 1 location
• A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
  NCT07293247 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 74 locations
• Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
  NCT06616584 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 386 locations
• CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
  NCT05733000 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer
  NCT06249282 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
  NCT06096844 · Phase: Phase 3 · Ages: 70 Years and older · Sex: All (male and female) · 324 locations
• Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
  NCT05642572 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 454 locations
• Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
  NCT06731270 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
  NCT07017829 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
  NCT04119024 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• Gilteritinib for the Treatment of ALK NSCLC
  NCT06225427 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
  NCT06518057 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
  NCT07288034 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
  NCT04181060 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 603 locations
• PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer
  NCT04151940 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
  NCT05269381 · Phase: Phase 1, Phase 2 · Ages: 16 Years and older · Sex: All (male and female) · 2 locations
• Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation
  NCT06110572 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer
  NCT06910761 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Q702 for the Treatment of Patients With Hematologic Malignancies
  NCT06712810 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
  NCT07322341 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
  NCT07012031 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study
  NCT05802186 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
  NCT06116682 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 248 locations
• Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
  NCT06031688 · Phase: Phase 2 · Ages: 18 Minutes and older · Sex: All (male and female) · 266 locations
• Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer
  NCT07423585 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer
  NCT07323641 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
  NCT06500455 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 270 locations
• Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
  NCT04665739 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 29 locations
• Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
  NCT03191149 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 344 locations
• Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
  NCT06500481 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 58 locations
• Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
  NCT04804644 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 231 locations
• Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
  NCT04402788 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 415 locations
• Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
  NCT04267848 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1151 locations
• Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
  NCT05198830 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 34 locations
• Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
  NCT06287775 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 43 locations
• Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast or Lung Cancer
  NCT05746325 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
  NCT06769126 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 148 locations
• Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
  NCT06616623 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many trials study Magnetic Resonance Imaging for Lung cancer?

38 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.